<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433160</url>
  </required_header>
  <id_info>
    <org_study_id>10494</org_study_id>
    <secondary_id>B3D-JE-GHDB</secondary_id>
    <nct_id>NCT00433160</nct_id>
  </id_info>
  <brief_title>Phase 3 Clinical Trial of Teriparatide in Japan</brief_title>
  <official_title>Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of teriparatide based on measurements of bone mineral density at
      lumbar spine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)</measure>
    <time_frame>Baseline to 52 Weeks</time_frame>
    <description>Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at Total Hip</measure>
    <time_frame>Baseline to 52 Weeks</time_frame>
    <description>Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at Femoral Neck</measure>
    <time_frame>Baseline to 52 Weeks</time_frame>
    <description>Percent change in bone mineral density at femoral neck from baseline to the last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP)</measure>
    <time_frame>Baseline to Weeks 4, 12, 24, and 52</time_frame>
    <description>Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP)</measure>
    <time_frame>Baseline to Weeks 4, 12, 24, 52</time_frame>
    <description>Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Biochemical Markers of Bone Metabolism - Serum Type I Collagen Crosslinked C-telopeptide (CTX)</measure>
    <time_frame>Baseline to Weeks 4, 12, 24, 52</time_frame>
    <description>Percent change in serum type I collagen crosslinked C-telopeptide (CTX) from baseline to the individual visits and last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertebral Fractures by Central X-ray Assessment</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Number of vertebral fractures observed from Visit 1 (study entry) through Visit 19 (Week 52). All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractures by Investigators Assessment</measure>
    <time_frame>Baseline through 52 Weeks</time_frame>
    <description>Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be &quot;fragility&quot; if they occurred without trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back Pain Severity</measure>
    <time_frame>Baseline, Weeks 12, 24, 36, 52</time_frame>
    <description>Severity of back pain at baseline, individual visits and the last measurement point. Back pain was measured on a scale of 1 (none) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4) During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at Total Hip During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at Femoral Neck During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Percent change in bone mineral density at femoral neck from baseline to the last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP) During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP) During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Biochemical Markers of Bone Metabolism - Serum Type I Collagen Crosslinked C-telopeptide (CTX) During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Percent change in serum type I collagen crosslinked C-telepeptide (CTX) from baseline to the individual visits and last measurement point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertebral Fractures by Central X-ray Assessment During Entire Study Period of 104 Weeks</measure>
    <time_frame>Baseline through 104 Weeks</time_frame>
    <description>Number of vertebral fractures observed from Visit 1 (study entry) through 104 weeks. All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractures by Investigators Assessment During Entire Study Period of 104 Weeks</measure>
    <time_frame>Baseline Through 104 Weeks</time_frame>
    <description>Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be &quot;fragility&quot; if they occurred without trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back Pain Severity During Open Label Phases at 76 Weeks and 104 Weeks</measure>
    <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
    <description>Severity of back pain at 76 weeks and 104 weeks. Back pain was measured on a scale of 1 (none) to 4 (severe).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 micrograms for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>daily, subcutaneous</description>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LY333334</other_name>
    <other_name>Forteo</other_name>
    <other_name>Forsteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>daily, subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients diagnosed with osteoporosis

          -  Aged 55 or older

          -  Patients who are at high risk for fracture

        Exclusion Criteria:

          -  History of metabolic bone disorders other than primary osteoporosis

          -  History of malignant neoplasm in the 5 years, with the exception of superficial basal
             cell carcinoma or squamous cell carcinoma of the skin that has been definitively
             treated.

          -  Severe or chronically disabling conditions other than osteoporosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>454-0933</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-2101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>070-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>655-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iwate</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagano</city>
        <zip>386-0493</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagasaki</city>
        <zip>854-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oita</city>
        <zip>879-7125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>555-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>358-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shimane</city>
        <zip>693-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>163-0202</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tottori</city>
        <zip>683-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <results_reference>
    <citation>Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone. 2010 Sep;47(3):493-502. doi: 10.1016/j.bone.2010.05.022. Epub 2010 May 24.</citation>
    <PMID>20580870</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2007</study_first_posted>
  <results_first_submitted>August 17, 2009</results_first_submitted>
  <results_first_submitted_qc>August 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2009</results_first_posted>
  <last_update_submitted>September 14, 2010</last_update_submitted>
  <last_update_submitted_qc>September 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Results from 4 patients aren't included in baseline and outcomes: 3 (2 placebo and 1 teriparatide) didn't receive study drug; 1 (placebo) had a significant good clinical practice issue of receiving study drug assigned to another patient.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Teriparatide</title>
          <description>20 micrograms for 104 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>52-Week Double-Blind (DB) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Exclusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>76 Weeks, 24-Week Open Label (OL) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119">One participant did not continue to first OL period due to adverse event after completing DB period.</participants>
                <participants group_id="P2" count="59">One participant did not continue to first OL period due to adverse event after completing DB period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>104 Weeks, 28-Week OL Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102">Eleven participants withdrew at end of first OL period and did not continue on to second OL period.</participants>
                <participants group_id="P2" count="50">Five participants withdrew at end of first OL period and did not continue on to second OL period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Teriparatide</title>
          <description>20 micrograms for 104 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="6.3"/>
                    <measurement group_id="B2" value="70.4" spread="5.4"/>
                    <measurement group_id="B3" value="69.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Vertebral Fractures</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 or More Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Osteoporosis Drug Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared (kg/m^2).</description>
          <units>kilograms per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.58" spread="3.03"/>
                    <measurement group_id="B2" value="22.24" spread="3.34"/>
                    <measurement group_id="B3" value="21.80" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone Mineral Density (BMD) Total Spine</title>
          <units>grams per square centimeter (g/cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6153" spread="0.0701"/>
                    <measurement group_id="B2" value="0.6123" spread="0.0780"/>
                    <measurement group_id="B3" value="0.6143" spread="0.0726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150.40" spread="5.97"/>
                    <measurement group_id="B2" value="150.30" spread="5.74"/>
                    <measurement group_id="B3" value="150.36" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.74" spread="6.83"/>
                    <measurement group_id="B2" value="50.25" spread="8.10"/>
                    <measurement group_id="B3" value="49.24" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4)</title>
        <description>Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.</description>
        <time_frame>Baseline to 52 weeks</time_frame>
        <population>Number of randomized participants with at least one dose of study drug and at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4)</title>
          <description>Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.</description>
          <population>Number of randomized participants with at least one dose of study drug and at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Last Measurement Point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.82" spread="5.36"/>
                    <measurement group_id="O2" value="0.04" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in bone mineral density at lumbar spine (L2-L4) after 52-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Last Measurement Point. No adjustments for multiplicity was performed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)</title>
        <description>Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.</description>
        <time_frame>Baseline to 52 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)</title>
          <description>Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Last Measurement Point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23" spread="5.74"/>
                    <measurement group_id="O2" value="0.11" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at Total Hip</title>
        <description>Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.</description>
        <time_frame>Baseline to 52 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at Total Hip</title>
          <description>Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Last Measurement Point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="4.22"/>
                    <measurement group_id="O2" value="-0.22" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at Femoral Neck</title>
        <description>Percent change in bone mineral density at femoral neck from baseline to the last measurement point.</description>
        <time_frame>Baseline to 52 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at Femoral Neck</title>
          <description>Percent change in bone mineral density at femoral neck from baseline to the last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Last Measurement Point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="6.01"/>
                    <measurement group_id="O2" value="0.46" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP)</title>
        <description>Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.</description>
        <time_frame>Baseline to Weeks 4, 12, 24, and 52</time_frame>
        <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP)</title>
          <description>Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.</description>
          <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in PINP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 4 (n=136, n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.67" spread="49.85"/>
                    <measurement group_id="O2" value="-9.58" spread="14.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 12 (n=131, n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.58" spread="66.58"/>
                    <measurement group_id="O2" value="-16.89" spread="17.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 24 (n=127, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.12" spread="112.04"/>
                    <measurement group_id="O2" value="-19.10" spread="29.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 52 (n=121, n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.11" spread="139.72"/>
                    <measurement group_id="O2" value="-14.18" spread="29.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Last Measurement (n=136,n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.74" spread="134.38"/>
                    <measurement group_id="O2" value="-13.82" spread="28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in PINP after 4-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 4. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in PINP after 12-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 12. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in PINP after 24-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 24. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in PINP after 52-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 52. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in PINP from baseline to the last measurement point between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Last Measurement. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP)</title>
        <description>Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.</description>
        <time_frame>Baseline to Weeks 4, 12, 24, 52</time_frame>
        <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP)</title>
          <description>Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.</description>
          <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BAP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 4 (n=135, n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" spread="37.86"/>
                    <measurement group_id="O2" value="-9.63" spread="33.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 12 (n=131, n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="49.05"/>
                    <measurement group_id="O2" value="-16.97" spread="40.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 24 (n=127, n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.60" spread="43.44"/>
                    <measurement group_id="O2" value="-28.46" spread="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 52 (n=120, n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.69" spread="58.12"/>
                    <measurement group_id="O2" value="-32.24" spread="46.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Last Measurement (n=136, n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.32" spread="56.06"/>
                    <measurement group_id="O2" value="-28.34" spread="46.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in BAP after 4-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 4. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in BAP after 12-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 12. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in BAP after 24-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 24. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in BAP after 52-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <p_value_desc>P-value for Percent Change to Week 52. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wicoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in BAP from baseline to the last measurement point between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.130</p_value>
            <p_value_desc>P-value for Percent Change to Last Measurement. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Biochemical Markers of Bone Metabolism  Serum Type I Collagen Crosslinked C-telopeptide (CTX)</title>
        <description>Percent change in serum type I collagen crosslinked C-telopeptide (CTX) from baseline to the individual visits and last measurement point.</description>
        <time_frame>Baseline to Weeks 4, 12, 24, 52</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Biochemical Markers of Bone Metabolism  Serum Type I Collagen Crosslinked C-telopeptide (CTX)</title>
          <description>Percent change in serum type I collagen crosslinked C-telopeptide (CTX) from baseline to the individual visits and last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in CTX</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 4 (n=124, n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" spread="40.73"/>
                    <measurement group_id="O2" value="-2.05" spread="28.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 12 (n=121, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.52" spread="69.52"/>
                    <measurement group_id="O2" value="-3.56" spread="27.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 24 (n=119, n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.27" spread="110.54"/>
                    <measurement group_id="O2" value="4.39" spread="37.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 52 (n=113, n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.81" spread="124.23"/>
                    <measurement group_id="O2" value="13.50" spread="39.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Last Measurement (n=126, n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.41" spread="119.61"/>
                    <measurement group_id="O2" value="11.64" spread="38.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in CTX after 4-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.976</p_value>
            <p_value_desc>P-value for Percent Change to Week 4. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in CTX after 12-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 12. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in CTX after 24-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 24. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in CTX after 52-week treatment between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Week 52. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the percent change in CTX from baseline to the last measurement point between the two treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Percent Change to Last Measurement. No adjustment for multiplicity was performed.</p_value_desc>
            <method>Wilcoxon's Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vertebral Fractures by Central X-ray Assessment</title>
        <description>Number of vertebral fractures observed from Visit 1 (study entry) through Visit 19 (Week 52). All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement. The n's are the number of participants with fractures.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Vertebral Fractures by Central X-ray Assessment</title>
          <description>Number of vertebral fractures observed from Visit 1 (study entry) through Visit 19 (Week 52). All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement. The n's are the number of participants with fractures.</population>
          <units>number of fractures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New Fractures (n=5, n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening Fractures (n=2, n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractures by Investigators Assessment</title>
        <description>Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be &quot;fragility&quot; if they occurred without trauma.</description>
        <time_frame>Baseline through 52 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fractures by Investigators Assessment</title>
          <description>Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be &quot;fragility&quot; if they occurred without trauma.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>number of fractures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vertebral Fracture - Fragility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertebral Fracture - Traumatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Vertebra Fracture - Fragility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Vertebra Fracture - Traumatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Back Pain Severity</title>
        <description>Severity of back pain at baseline, individual visits and the last measurement point. Back pain was measured on a scale of 1 (none) to 4 (severe).</description>
        <time_frame>Baseline, Weeks 12, 24, 36, 52</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Back Pain Severity</title>
          <description>Severity of back pain at baseline, individual visits and the last measurement point. Back pain was measured on a scale of 1 (none) to 4 (severe).</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: 1 - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 2 - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 4 - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: 1 - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: 2 - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: 3 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: 4 - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: 1 - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: 2 - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: 3 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: 4 - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: 1 - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: 2 - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: 3 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: 4 - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: 1 - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: 2 - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: 3 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: 4 - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Measurement: 1 - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Measurement: 2 - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Measurement: 3 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Measurement: 4 - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4) During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants with at least one dose of study drug and at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4) During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.</description>
          <population>Number of randomized participants with at least one dose of study drug and at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 76; n=113, n=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.93" spread="5.79"/>
                    <measurement group_id="O2" value="6.39" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 104; n=92, n=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.42" spread="6.12"/>
                    <measurement group_id="O2" value="9.11" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 76; n=113, n=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.24" spread="5.86"/>
                    <measurement group_id="O2" value="6.63" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 104; n=92, n=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.01" spread="6.41"/>
                    <measurement group_id="O2" value="9.46" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at Total Hip During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at Total Hip During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 76; n=112, n=54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="3.79"/>
                    <measurement group_id="O2" value="1.64" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 104; n=91, n=46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="3.98"/>
                    <measurement group_id="O2" value="2.46" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at Femoral Neck During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Percent change in bone mineral density at femoral neck from baseline to the last measurement point.</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at Femoral Neck During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Percent change in bone mineral density at femoral neck from baseline to the last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 76; n=112, n=54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="4.45"/>
                    <measurement group_id="O2" value="1.17" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 104; n=91, n=46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="4.25"/>
                    <measurement group_id="O2" value="2.19" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP) During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP) During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.</description>
          <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in PINP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change to Week 76; n=113, n=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.45" spread="174.07"/>
                    <measurement group_id="O2" value="97.28" spread="131.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change to Week 104; n=92, n=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.71" spread="112.48"/>
                    <measurement group_id="O2" value="134.89" spread="180.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP) During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP) During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.</description>
          <population>Number of randomized participants with at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in BAP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 76; n=113, n=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.49" spread="66.40"/>
                    <measurement group_id="O2" value="15.71" spread="64.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 104; n=92, n=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="54.38"/>
                    <measurement group_id="O2" value="16.45" spread="71.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Type I Collagen Crosslinked C-telopeptide (CTX) During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Percent change in serum type I collagen crosslinked C-telepeptide (CTX) from baseline to the individual visits and last measurement point.</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Biochemical Markers of Bone Metabolism - Serum Type I Collagen Crosslinked C-telopeptide (CTX) During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Percent change in serum type I collagen crosslinked C-telepeptide (CTX) from baseline to the individual visits and last measurement point.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>percent change in CTX</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change to Week 76; n=104, n=53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.85" spread="137.13"/>
                    <measurement group_id="O2" value="86.98" spread="132.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change to Week 104; n=85, n=45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.39" spread="111.97"/>
                    <measurement group_id="O2" value="72.84" spread="100.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vertebral Fractures by Central X-ray Assessment During Entire Study Period of 104 Weeks</title>
        <description>Number of vertebral fractures observed from Visit 1 (study entry) through 104 weeks. All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.</description>
        <time_frame>Baseline through 104 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least on post-treatment measurement. The n's are the number of participants with fractures.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Vertebral Fractures by Central X-ray Assessment During Entire Study Period of 104 Weeks</title>
          <description>Number of vertebral fractures observed from Visit 1 (study entry) through 104 weeks. All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least on post-treatment measurement. The n's are the number of participants with fractures.</population>
          <units>number of fractures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New Fractures at 104 Weeks (n=5, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening Fractures at 104 Weeks (n=2, n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractures by Investigators Assessment During Entire Study Period of 104 Weeks</title>
        <description>Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be &quot;fragility&quot; if they occurred without trauma.</description>
        <time_frame>Baseline Through 104 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fractures by Investigators Assessment During Entire Study Period of 104 Weeks</title>
          <description>Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be &quot;fragility&quot; if they occurred without trauma.</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least one post-treatment measurement.</population>
          <units>number of fractures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vertebral Fracture - Fragility - 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertebral Fracture - Traumatic - 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Vertebra Fracture - Fragility - 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Vertebra Fracture - Traumatic - 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Back Pain Severity During Open Label Phases at 76 Weeks and 104 Weeks</title>
        <description>Severity of back pain at 76 weeks and 104 weeks. Back pain was measured on a scale of 1 (none) to 4 (severe).</description>
        <time_frame>Baseline, 76 Weeks, 104 Weeks</time_frame>
        <population>Number of randomized participants who received at least one dose of study drug and with at least on post-treatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>20 micrograms for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Back Pain Severity During Open Label Phases at 76 Weeks and 104 Weeks</title>
          <description>Severity of back pain at 76 weeks and 104 weeks. Back pain was measured on a scale of 1 (none) to 4 (severe).</description>
          <population>Number of randomized participants who received at least one dose of study drug and with at least on post-treatment measurement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76: 1- None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76: 2- Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76: 3- Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76: 4- Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104: 1- None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104: 2- Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104: 3- Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104: 4- Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events and Other Adverse Events are reported for both treatment arms for the following time frames: double-blind treatment (During 52 weeks); open-label treatment (During 76 weeks); open-label treatment (During 104 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Teriparatide (During 52 Weeks)</title>
          <description>20 micrograms for 104 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo (During 52 Weeks)</title>
          <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
        </group>
        <group group_id="E3">
          <title>Teriparatide (During 76 Weeks)</title>
          <description>20 micrograms for 104 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo (During 76 Weeks)</title>
          <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
        </group>
        <group group_id="E5">
          <title>Teriparatide (During 104 Weeks)</title>
          <description>20 micrograms for 104 weeks</description>
        </group>
        <group group_id="E6">
          <title>Placebo (During 104 Weeks)</title>
          <description>Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="125" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" events="15" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" events="14" subjects_affected="8" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" events="15" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="66" subjects_affected="38" subjects_at_risk="136"/>
                <counts group_id="E2" events="37" subjects_affected="27" subjects_at_risk="67"/>
                <counts group_id="E3" events="89" subjects_affected="45" subjects_at_risk="136"/>
                <counts group_id="E4" events="51" subjects_affected="29" subjects_at_risk="67"/>
                <counts group_id="E5" events="113" subjects_affected="55" subjects_at_risk="136"/>
                <counts group_id="E6" events="68" subjects_affected="32" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" events="16" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E6" events="12" subjects_affected="11" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="136"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="136"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E5" events="33" subjects_affected="25" subjects_at_risk="136"/>
                <counts group_id="E6" events="23" subjects_affected="16" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" events="16" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" events="18" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" events="15" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" events="16" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" events="22" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental care</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="10" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" events="11" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Original data presented were for the 52-week double-blinded treatment phase; results of the open label phases at 76 weeks and 104 weeks have now been added</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

